BANGALORE, Aug 19 (Reuters) - U.S. drugmaker Alexion Pharmaceuticals (ALXN.O) said Novartis (NOVN.VX) challenged the European patent covering its key genetic disorder drug Soliris, in what analysts said was an attempt by the Swiss giant to clear the way for its own experimental eye drug.
